Hims & Hers has carved a strong niche in the men's healthcare segment while expanding into other areas. The weight-loss category is a huge opportunity for the company.

Eli Lilly's Zepbound got a 50% price cut that could take some of Hims & Hers growth potential. Lower-cost drugs could be good news for Hims & Hers long term.

The new option is priced at a 50% or more discount compared to other weight-loss drugs.

Hims & Hers Health, Inc. reported booming sales in Q2, but the stock fell due to possible confusion on compounded GLP-1 drug sales. The online health and wellness platform dramatically hiked Q3 sal...

Hims & Hers stock is trading based on speculation about its success with weight loss drugs. But that's a very small part of its business.

Novo Nordisk and Eli Lilly are currently the major players in the weight loss market. Hims & Hers Health is looking to disrupt the space by offering a lower-cost alternative.

Hims & Hers' revenue and profit metrics soared in the second quarter. Growth is expected to accelerate in the second half following the launch of the company's GLP-1 offering.

Don't overlook the 52% growth in the second quarter.

Hims & Hers Health, Inc. (HIMS) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.05 per share. This compares to loss of $0.03 per share a year ago.

Hims & Hers (HIMS) is enhancing its offerings and expanding the breadth of health and wellness products and services. However, macro challenges are likely to hurt its performance.

After a late-May bull gap on the charts, healthcare stock Hims & Hers Health Inc (NYSE:HIMS) steadily worked higher to snag a record high of $25.74 on June 18.

Continued solid uptake of Hims & Hers (HIMS) offerings and expanding subscriber base are likely to have driven its performance in the second quarter.

Hims & Hers' unique, brand-driven strategy can help it establish a moat in the competitive telehealth industry. Over the long term, the company can leverage user data and artificial intelligence to...

Hims & Hers Health, Inc. NYSE: HIMS is a prominent player in the telehealth sector, which is part of the larger healthcare sector.  The company has garnered significant attention from investors due...

These companies are on different growth trajectories, but each has something to offer long-term investors. Hims & Hers is increasing subscribers and revenue rapidly, while profitability is expanding.